Should I buy or sell Precigen stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares. View PGEN analyst ratings or view top-rated stocks .

What is Precigen's stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 747.5% from the stock's current price. View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts .

How have PGEN shares performed in 2023?

Precigen's stock was trading at $1.52 at the start of the year. Since then, PGEN stock has decreased by 22.4% and is now trading at $1.18. View the best growth stocks for 2023 here .

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our PGEN earnings forecast .

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $1.38 million for the quarter, compared to the consensus estimate of $2.68 million. Precigen had a negative net margin of 1,257.75% and a negative trailing twelve-month return on equity of 54.48%.

What ETF holds Precigen's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP) , Nordic American Tankers (NAT) , Hess (HES) , Boeing (BA) , OPKO Health (OPK) , Celldex Therapeutics (CLDX) , TherapeuticsMD (TXMD) , Gilead Sciences (GILD) , NVIDIA (NVDA) and Bausch Health Companies (BHC) .

Who are Precigen's major shareholders?

Precigen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.44%), Charles Schwab Investment Management Inc. (0.42%), Jacobs Levy Equity Management Inc. (0.28%), Bank of New York Mellon Corp (0.18%) and Fore Capital LLC (0.17%). Insiders that own company stock include David M Obstler , Dean J Mitchell, Donald P Lehr , Harry Jr Thomasian , Helen Sabzevari , Jeffrey B Kindler, Jeffrey Thomas Perez , Jennifer I Ansberry, John N Digiacomo, Randal J Kirk , Rick L Sterling, Rutul R Shah, Steven Frank and Trading SA Ares. View institutional ownership trends .

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Precigen Stock Price, News & Analysis (NASDAQ:PGEN)

$1.18

+0.01 (+0.85%)

(As of 12/8/2023 ET)

Compare

Today's Range: $1.14
▼
$1.21
50-Day Range: $0.89
▼
$1.42
52-Week Range: $0.81
▼
$2.29

Volume: 832,960 shs
Average Volume: 1.82 million shs
Market Capitalization: $293.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Precigen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 747.5% Upside
$10.00 Price Target
Short Interest: Bearish
12.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$35,250 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.34) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

568th out of 954 stocks

Pharmaceutical Preparations Industry

202nd out of 362 stocks

3.4

Analyst's Opinion

Consensus Rating
Precigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Precigen has a forecasted upside of 747.5% from its current price of $1.18.
Amount of Analyst Coverage
Precigen has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
12.67% of the float of Precigen has been sold short.
Short Interest Ratio / Days to Cover
Precigen has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Precigen has recently increased by 2.33%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Precigen does not currently pay a dividend.
Dividend Growth
Precigen does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Precigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Precigen is -0.77.

0.0

News and Social Media Coverage

Search Interest
Only 6 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precigen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,250.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
41.70% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 22.48% of the stock of Precigen is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Precigen are expected to grow in the coming year, from ($0.34) to ($0.28) per share.
Price to Book Value per Share Ratio
Precigen has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Precigen Stock (NASDAQ:PGEN)

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PGEN Stock News Headlines

November 29, 2023 | finance.yahoo.com

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

November 22, 2023 | morningstar.com

Precigen Inc PGEN

December 9, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 11, 2023 | markets.businessinsider.com

Promising Pipeline Progress and Strong Financial Standing Justify Buy Rating for Precigen

November 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Precigen (PGEN)

November 9, 2023 | msn.com

Precigen GAAP EPS of -$0.08 in-line, revenue of $1.38M misses by $0.6M

November 9, 2023 | finance.yahoo.com

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

November 7, 2023 | finance.yahoo.com

Precigen to Participate in the Stifel 2023 Healthcare Conference

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 21, 2023 | uk.finance.yahoo.com

Precigen, Inc. (PGEN)

September 25, 2023 | finance.yahoo.com

While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership

September 19, 2023 | finance.yahoo.com

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

September 5, 2023 | finance.yahoo.com

Should You Buy Precigen, Inc. (PGEN) After Golden Cross?

August 25, 2023 | finance.yahoo.com

Is Precigen Inc Set to Underperform? Analyzing the Factors Limiting Growth

August 25, 2023 | finance.yahoo.com

Is Precigen (PGEN) Significantly Overvalued? A Comprehensive Valuation Analysis

August 17, 2023 | benzinga.com

Precigen Recent Insider Activity

August 17, 2023 | finance.yahoo.com

Fred Hassan Bought 185% More Shares In Precigen

August 13, 2023 | markets.businessinsider.com

Precigen (PGEN) Receives a Buy from Stifel Nicolaus

August 11, 2023 | finance.yahoo.com

Here's Why We're Watching Precigen's (NASDAQ:PGEN) Cash Burn Situation

August 10, 2023 | msn.com

HC Wainwright & Co. Reiterates Precigen (PGEN) Buy Recommendation

August 10, 2023 | finance.yahoo.com

PGEN - Precigen, Inc.

August 10, 2023 | markets.businessinsider.com

Precigen (PGEN) Receives a Buy from H.C. Wainwright

August 9, 2023 | seekingalpha.com

Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript

August 9, 2023 | msn.com

Precigen Phase 1/2 trial selected as a pivotal study for rare disease therapy

August 9, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Precigen (PGEN)

August 9, 2023 | seekingalpha.com

Precigen Q2 2023 Earnings Preview

August 9, 2023 | finance.yahoo.com

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

See More Headlines

Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PGEN
CUSIP: N/A
CIK: 1356090
Web: www.precigen.com
Phone: (301) 556-9900
Fax: N/A
Employees: 209
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $14.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +747.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $28.32 million
Net Margins: -1,257.75%
Pretax Margin: -1,259.50%
Return on Equity: -54.48%
Return on Assets: -39.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.83
Quick Ratio: 2.83

Sales & Book Value

Annual Sales: $6.76 million
Price / Sales: 43.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 248,919,000
Free Float: 145,120,000
Market Cap: $293.72 million
Optionable: Optionable
Beta: 1.80

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Randal J. Kirk J.D. (Age 70)
Executive Chairman
Comp: $100k
Dr. Helen Sabzevari MPH (Age 61)
Ph.D., President, CEO & Director
Comp: $1.29M
Mr. Harry Thomasian Jr. (Age 60)
Chief Financial Officer
Comp: $524.04k
Mr. Rutul R. Shah (Age 42)
Chief Operating Officer
Comp: $393.54k
Mr. Donald P. Lehr (Age 48)
Chief Legal Officer & Corporate Secretary
Comp: $652.4k
Mr. Jeffrey Thomas Perez (Age 51)
Senior Vice President of Intellectual Property Affairs
Comp: $570.24k
Dr. Thomas D. Reed Ph.D. (Age 57)
Founder & Chief Science Officer
Comp: $572.72k
Mr. Steven Harasym
VP & Head of Investor Relations
Marie Rossi
Vice President of Communications
Mr. Rob Russell
VP & Head of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Precigen stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PGEN shares.
View PGEN analyst ratings or view top-rated stocks.
What is Precigen's stock price target for 2024?: 4 Wall Street analysts have issued 12 month price targets for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 747.5% from the stock's current price.
View analysts price targets for PGEN or view top-rated stocks among Wall Street analysts.
How have PGEN shares performed in 2023?: Precigen's stock was trading at $1.52 at the start of the year. Since then, PGEN stock has decreased by 22.4% and is now trading at $1.18.
View the best growth stocks for 2023 here.
When is Precigen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our PGEN earnings forecast.
How were Precigen's earnings last quarter?: Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The biotechnology company had revenue of $1.38 million for the quarter, compared to the consensus estimate of $2.68 million. Precigen had a negative net margin of 1,257.75% and a negative trailing twelve-month return on equity of 54.48%.

What ETF holds Precigen's stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio.
What other stocks do shareholders of Precigen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).
Who are Precigen's major shareholders?: Precigen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.44%), Charles Schwab Investment Management Inc. (0.42%), Jacobs Levy Equity Management Inc. (0.28%), Bank of New York Mellon Corp (0.18%) and Fore Capital LLC (0.17%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends.
How do I buy shares of Precigen?: Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PGEN) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial